2020
DOI: 10.1016/j.celrep.2020.108468
|View full text |Cite
|
Sign up to set email alerts
|

SHP-1 Regulates Antigen Cross-Presentation and Is Exploited by Leishmania to Evade Immunity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
10
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(11 citation statements)
references
References 45 publications
1
10
0
Order By: Relevance
“…Activation of PTPN6/SHP-1, in addition to regulating innate immunity, suppresses antigen cross-presentation (Ding et al, 2016), which some pathogens exploit to subvert adaptive immunity (C. Khouili et al, 2020). Further support for our finding of inter-individual variation in PTPN6/SHP-1 activity thus would have immediate implications both for understanding variations in pathogen susceptibility and for personalizing DC vaccines aimed at initiating CD8 T-cell responses.…”
Section: Discussionsupporting
confidence: 63%
“…Activation of PTPN6/SHP-1, in addition to regulating innate immunity, suppresses antigen cross-presentation (Ding et al, 2016), which some pathogens exploit to subvert adaptive immunity (C. Khouili et al, 2020). Further support for our finding of inter-individual variation in PTPN6/SHP-1 activity thus would have immediate implications both for understanding variations in pathogen susceptibility and for personalizing DC vaccines aimed at initiating CD8 T-cell responses.…”
Section: Discussionsupporting
confidence: 63%
“…Third, in PTPN6/SHP-1 we identify a specific factor that contributes to this 283 variation, revealing how our approach enables dissecting the genetic bases of such inter-284 individual variation. Activation of PTPN6/SHP-1, in addition to regulating innate immunity, 285 suppresses antigen cross-presentation (Ding et al, 2016), which some pathogens exploit to 286 subvert adaptive immunity (C. Khouili et al, 2020). Our finding of inter-individual variation in 287 PTPN6/SHP-1 activity thus has immediate implications both for understanding variations in 288 14 pathogen susceptibility and for personalizing DC vaccines aimed at initiating CD8 T-cell responses.…”
Section: Discussionmentioning
confidence: 89%
“…Intriguingly, PRM targeted analysis revealed that PTPN6 was significantly downregulated in PCP B cell exosomes. SHP-1 (PTPN6) exerts its regulatory role on T cells by inhibiting antigen-dependent activation and proliferation in Leishmania infection and other inflammatory conditions [ 49 , 50 ]. Moreover, in a tumor model of melanoma, knockdown of SHP-1 (PTPN6) expands antitumor T cell repertoire and dampens tumor growth, suggesting the potential application of SHP-1 (PTPN6) as immune checkpoint in future immune therapy [ 51 ].…”
Section: Discussionmentioning
confidence: 99%